{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:08:21Z","timestamp":1790726901142,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020027","name":"Dr Rolf M Schwiete Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["slas-discovery.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["SLAS Discovery"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.slasd.2026.100337","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:22:39Z","timestamp":1788949359000},"page":"100337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["High-content imaging workflow for single-cell drug response profiling of acute myeloid leukemia subtypes"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0168-1093","authenticated-orcid":false,"given":"Laura","family":"Isigkeit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekia","family":"Sinderwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajlin","family":"Ismaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9101-260X","authenticated-orcid":false,"given":"Sina","family":"Oppermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.slasd.2026.100337_bib0001","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.3390\/ijms23052863","article-title":"Application of high throughput technologies in the development of acute myeloid leukemia therapy: challenges and progress","volume":"23","author":"Xiang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.slasd.2026.100337_bib0002","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.slasd.2026.100337_bib0003","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanm\u00e4ki","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.slasd.2026.100337_bib0004","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41419-024-06810-7","article-title":"Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia","volume":"15","author":"Nwosu","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.slasd.2026.100337_bib0005","article-title":"Ex vivo chemosensitivity profiling of acute myeloid leukemia and its correlation with clinical response and outcome to chemotherapy","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.slasd.2026.100337_bib0006","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.slasd.2026.100337_bib0007","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/2159-8290.CD-21-0094","article-title":"The pediatric precision oncology INFORM Registry: clinical outcome and benefit for patients with very high-evidence targets","volume":"11","author":"van Tilburg","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.slasd.2026.100337_bib0008","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","article-title":"The NCI-MATCH trial: lessons for precision oncology","volume":"29","author":"O'Dwyer","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.slasd.2026.100337_bib0009","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70129","article-title":"Comparing functional and genomic-based precision medicine in blood cancer patients","volume":"9","author":"Kazianka","year":"2025","journal-title":"Hemasphere"},{"key":"10.1016\/j.slasd.2026.100337_bib0010","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41698-022-00335-y","article-title":"Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM","volume":"6","author":"Peterziel","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.slasd.2026.100337_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1275251","article-title":"Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches","volume":"14","author":"Bhatia","year":"2024","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.slasd.2026.100337_bib0012","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.3324\/haematol.2022.281692","article-title":"Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia","volume":"108","author":"Kuusanm\u00e4ki","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.slasd.2026.100337_bib0013","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3390\/cancers13040748","article-title":"Descriptive and functional genomics in acute myeloid leukemia (AML): paving the road for a cure","volume":"13","author":"Pasquer","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.slasd.2026.100337_bib0014","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s40364-025-00839-2","article-title":"Emerging strategies and novel therapeutic targets in acute myeloid leukemia: current advances and future directions","volume":"13","author":"Cao","year":"2025","journal-title":"Biomark Res"},{"key":"10.1016\/j.slasd.2026.100337_bib0015","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/s41467-021-22625-y","article-title":"A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia","volume":"12","author":"Docking","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.slasd.2026.100337_bib0016","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","article-title":"Implementing a functional precision medicine tumor board for acute myeloid leukemia","volume":"12","author":"Malani","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.slasd.2026.100337_bib0017","doi-asserted-by":"crossref","first-page":"9402","DOI":"10.1038\/s41467-024-53535-4","article-title":"Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia","volume":"15","author":"Wegmann","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.slasd.2026.100337_bib0018","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41591-024-02848-4","article-title":"Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers","volume":"30","author":"La Acanda de Rocha","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.slasd.2026.100337_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105996","article-title":"iTReX: interactive exploration of mono- and combination therapy dose response profiling data","volume":"175","author":"ElHarouni","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.slasd.2026.100337_bib0020","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcyt.2023.10.005","article-title":"Review of flow cytometry as a tool for cell and gene therapy","volume":"26","author":"Lazarski","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.slasd.2026.100337_bib0021","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.3390\/ijms25073851","article-title":"Applications of flow cytometry in drug discovery and translational research","volume":"25","author":"Ullas","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.slasd.2026.100337_bib0022","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1016\/S2352-3026(17)30208-9","article-title":"Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study","volume":"4","author":"Snijder","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.slasd.2026.100337_bib0023","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood-2015-12-687814","article-title":"High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells","volume":"128","author":"Oppermann","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.slasd.2026.100337_bib0024","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1109\/TMI.2022.3205554","article-title":"Patient-by-Patient deep transfer learning for drug-response profiling using confocal fluorescence microscopy of pediatric Patient-derived tumor-cell spheroids","volume":"41","author":"Berker","year":"2022","journal-title":"IEEE Trans Med Imaging"},{"key":"10.1016\/j.slasd.2026.100337_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.114216","article-title":"High-content imaging of primary chronic lymphocytic leukemia cells predicts patient cohorts with distinct cellular drug responses","volume":"28","author":"Li","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.slasd.2026.100337_bib0026","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/nprot.2016.105","article-title":"Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes","volume":"11","author":"Bray","year":"2016","journal-title":"Nat Protoc"},{"key":"10.1016\/j.slasd.2026.100337_bib0027","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41568-023-00610-5","article-title":"Bridging live-cell imaging and next-generation cancer treatment","volume":"23","author":"Alieva","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.slasd.2026.100337_bib0028","article-title":"Image-based drug screening combined with molecular profiling identifies signatures and drivers of therapy resistance in pediatric AML","volume":"6","author":"Haladik","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.slasd.2026.100337_bib0029","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1158\/2643-3230.BCD-21-0219","article-title":"Deep morphology learning enhances ex vivo drug profiling-based precision medicine","volume":"3","author":"Heinemann","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.slasd.2026.100337_bib0030","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023154","article-title":"AML, ALL, and CML classification and diagnosis based on bone marrow cell morphology combined with convolutional neural network: a STARD compliant diagnosis research","volume":"99","author":"Huang","year":"2020","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.slasd.2026.100337_bib0031","series-title":"Methods and apparatus for fast identification of relevant features for classification or regression (Patent No. WO2013\/038224A1)","year":"2011"},{"key":"10.1016\/j.slasd.2026.100337_bib0032","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"4","author":"Yadav","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.slasd.2026.100337_bib0033","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41596-023-00903-x","article-title":"Robust scoring of selective drug responses for patient-tailored therapy selection","volume":"19","author":"Chen","year":"2024","journal-title":"Nat Protoc"},{"key":"10.1016\/j.slasd.2026.100337_bib0034","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-024-01033-7","article-title":"Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century","volume":"14","author":"Hemminki","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.slasd.2026.100337_bib0035","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","article-title":"a cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia","volume":"28","author":"Zeng","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.slasd.2026.100337_bib0036","article-title":"Quantitative spectrofluorometric assay detecting nuclear condensation and fragmentation in intact cells","volume":"11","author":"Majtnerova","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.slasd.2026.100337_bib0037","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2144\/000113610","article-title":"Mitochondrial membrane potential probes and the proton gradient: a practical usage guide","volume":"50","author":"Perry","year":"2011","journal-title":"Biotechniques"},{"key":"10.1016\/j.slasd.2026.100337_bib0038","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41420-025-02391-2","article-title":"Comprehensive analysis of cellular metrics: from proliferation to mitochondrial membrane potential and cell death in a single sample","volume":"11","author":"Sabirova","year":"2025","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.slasd.2026.100337_bib0039","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12032-017-0970-x","article-title":"FLT3-ITD and its current role in acute myeloid leukaemia","volume":"34","author":"Lagunas-Rangel","year":"2017","journal-title":"Med Oncol"},{"key":"10.1016\/j.slasd.2026.100337_bib0040","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/adt.2006.042","article-title":"Mixing in 384-well plates: issues, measurements, and solutions","volume":"5","author":"Walling","year":"2007","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.slasd.2026.100337_bib0041","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/1087057109357787","article-title":"Confocal-based method for quantification of diffusion kinetics in microwell plates and its application for identifying a rapid mixing method for high-content\/throughput screening","volume":"15","author":"Song","year":"2010","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.slasd.2026.100337_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R","article-title":"Annexin v-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure","volume":"31","author":"van Engeland","year":"1998","journal-title":"Cytometry"},{"key":"10.1016\/j.slasd.2026.100337_bib0043","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.leu.2402740","article-title":"FLT3 mutations in acute myeloid leukemia cell lines","volume":"17","author":"Quentmeier","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.slasd.2026.100337_bib0044","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/sj.leu.2403236","article-title":"Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations","volume":"18","author":"Drexler","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.slasd.2026.100337_bib0045","doi-asserted-by":"crossref","first-page":"943","DOI":"10.18632\/oncotarget.27489","article-title":"Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells","volume":"11","author":"Aikawa","year":"2020","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.slasd.2026.100337_bib0046","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3324\/haematol.2018.191650","article-title":"MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin","volume":"103","author":"Seipel","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.slasd.2026.100337_bib0047","doi-asserted-by":"crossref","first-page":"8218","DOI":"10.1038\/s41598-019-44491-x","article-title":"The LL-100 panel: 100 cell lines for blood cancer studies","volume":"9","author":"Quentmeier","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.slasd.2026.100337_bib0048","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/10428190400007565","article-title":"The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia","volume":"46","author":"Larizza","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.slasd.2026.100337_bib0049","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/leu.2011.238","article-title":"The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations","volume":"26","author":"Tiacci","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.slasd.2026.100337_bib0050","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.slasd.2026.100337_bib0051","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-025-01215-x","article-title":"Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention","volume":"15","author":"Fonseca","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.slasd.2026.100337_bib0052","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood.2023019706","article-title":"Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy","volume":"143","author":"Liu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.slasd.2026.100337_bib0053","doi-asserted-by":"crossref","first-page":"107206","DOI":"10.18632\/oncotarget.22284","article-title":"Combined venetoclax and alvocidib in acute myeloid leukemia","volume":"8","author":"Bogenberger","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.slasd.2026.100337_bib0054","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1200\/JCO.2025.43.16_suppl.6537","article-title":"Overcoming acquired venetoclax resistance in acute myeloid leukemia through cell metabolism targeting","volume":"43","author":"Machado-Neto","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.slasd.2026.100337_bib0055","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00210-024-03599-2","article-title":"Flavopiridol: a promising cyclin-dependent kinase inhibitor in cancer treatment. Naunyn Schmiedeb","volume":"398","author":"Baghel","year":"2025","journal-title":"Arch Pharmacol"},{"key":"10.1016\/j.slasd.2026.100337_bib0056","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1002\/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J","article-title":"Paclitaxel-induced cell death","volume":"88","author":"Wang","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.slasd.2026.100337_bib0057","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02503-9","article-title":"The effect of paclitaxel on apoptosis, autophagy and mitotic catastrophe in AGS cells","volume":"11","author":"Khing","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.slasd.2026.100337_bib0058","first-page":"1339","article-title":"Vincristine induced apoptosis in acute lymphoblastic leukaemia cells: a mitochondrial controlled pathway regulated by reactive oxygen species?","volume":"21","author":"Groninger","year":"2002","journal-title":"Int J Oncol"},{"key":"10.1016\/j.slasd.2026.100337_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2022.105472","article-title":"Vincristine promotes differential levels of apoptosis, mitotic catastrophe, and senescence depending on the genetic background of glioblastoma cells","volume":"85","author":"Filippi-Chiela","year":"2022","journal-title":"Toxicol Vitro"},{"key":"10.1016\/j.slasd.2026.100337_bib0060","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","article-title":"Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders","volume":"12","author":"Kornauth","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.slasd.2026.100337_bib0061","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.3324\/haematol.2022.281214","article-title":"Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-na\u00efve acute myeloid leukemia","volume":"107","author":"Gangat","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.slasd.2026.100337_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106735","article-title":"RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed\/refractory acute myeloid leukemia","volume":"111","author":"Chow","year":"2021","journal-title":"Leuk Res"},{"key":"10.1016\/j.slasd.2026.100337_bib0063","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/ajh.25978","article-title":"Venetoclax and hypomethylating agents in acute myeloid leukemia: mayo Clinic series on 86 patients","volume":"95","author":"Morsia","year":"2020","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.slasd.2026.100337_bib0064","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3324\/haematol.2023.282921","article-title":"ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms","volume":"109","author":"Riabov","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.slasd.2026.100337_bib0065","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jconrel.2021.03.042","article-title":"Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia","volume":"333","author":"Chen","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.slasd.2026.100337_bib0066","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1158\/0008-5472.CAN-24-1938","article-title":"Integrative multiomics and drug sensitivity profiling reveal potential biomarkers and therapeutic strategies in pediatric solid tumors","volume":"86","author":"ElHarouni","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.slasd.2026.100337_bib0067","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nmeth.2847","article-title":"Identification of small molecules that support human leukemia stem cell activity ex vivo","volume":"11","author":"Pabst","year":"2014","journal-title":"Nat Methods"}],"container-title":["SLAS Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555226000432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555226000432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:47:22Z","timestamp":1790725642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2472555226000432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":67,"alternative-id":["S2472555226000432"],"URL":"https:\/\/doi.org\/10.1016\/j.slasd.2026.100337","relation":{},"ISSN":["2472-5552"],"issn-type":[{"value":"2472-5552","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-content imaging workflow for single-cell drug response profiling of acute myeloid leukemia subtypes","name":"articletitle","label":"Article Title"},{"value":"SLAS Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.slasd.2026.100337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Society for Laboratory Automation and Screening.","name":"copyright","label":"Copyright"}],"article-number":"100337"}}